Welcome to our dedicated page for Kodiak Sciences SEC filings (Ticker: KOD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kodiak Sciences Inc. (Nasdaq: KOD) SEC filings, offering insight into how the precommercial retina-focused biotechnology company reports its activities to regulators. Kodiak Sciences develops biologic therapeutics for retinal vascular diseases and macular edema secondary to inflammation (MESI), and its filings reflect the progress and funding of these programs.
Investors can review Form 8-K current reports where Kodiak discloses material events, such as quarterly financial results and business highlights, or the terms and completion of public offerings of common stock. For example, a December 18, 2025 Form 8-K describes the underwriting agreement and closing of an 8,000,000-share public offering that generated gross proceeds of approximately $184 million before expenses.
Through its shelf registration statement on Form S-3 and related prospectus supplements, Kodiak outlines how it may issue securities to finance its late-stage clinical programs, including Phase 3 studies like GLOW2, DAYBREAK, PEAK and PINNACLE. Additional filings, such as quarterly and annual reports when available, typically provide more detail on research and development expenses, cash position and the status of clinical trials for tarcocimab, KSI-501 and KSI-101.
On Stock Titan, users can view Kodiak’s latest SEC submissions as they are posted to EDGAR and use AI-powered tools to summarize complex documents. These tools can help explain offering terms, highlight key clinical and financial disclosures, and surface information on topics such as capital raising, research spending and trial milestones relevant to KOD.